Efficacy and safety of albumin-bound paclitaxel in the treatment of advanced non-small cell lung cancer

JI Peng; NING Lijuan; CHEN Yongwu; ZHU Pengli; WU Fei; WU Yingqi; YAN Hui; GENG Yadi; ZHANG Shengyu; SHEN Aizong

doi:10.6039/j.issn.1001-0408.2022.22.15

您当前的位置：

首页 >

文章列表页 >

Efficacy and safety of albumin-bound paclitaxel in the treatment of advanced non-small cell lung cancer

更新时间：2023-02-22

- Efficacy and safety of albumin-bound paclitaxel in the treatment of advanced non-small cell lung cancer
- ZHONGGUO YAOFANG Vol. 33, Issue 22, Pages: 2762-2765(2022)
- 作者机构：
  
  中国科学技术大学附属第一医院（安徽省立医院）药学部/安徽省药品临床综合评价技术中心，合肥　230001
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2022.22.15
  CLC： R979.1;R734.2
- Published：30 November 2022，
  
  Received：16 May 2022，
  
  Revised：26 August 2022，
扫描看全文
季鹏,宁丽娟,陈泳伍等.白蛋白结合型紫杉醇治疗晚期非小细胞肺癌的有效性和安全性 ^Δ[J].中国药房,2022,33(22):2762-2765.

JI Peng,NING Lijuan,CHEN Yongwu,et al.Efficacy and safety of albumin-bound paclitaxel in the treatment of advanced non-small cell lung cancer[J].ZHONGGUO YAOFANG,2022,33(22):2762-2765.
季鹏,宁丽娟,陈泳伍等.白蛋白结合型紫杉醇治疗晚期非小细胞肺癌的有效性和安全性 ^Δ[J].中国药房,2022,33(22):2762-2765. DOI： 10.6039/j.issn.1001-0408.2022.22.15.

JI Peng,NING Lijuan,CHEN Yongwu,et al.Efficacy and safety of albumin-bound paclitaxel in the treatment of advanced non-small cell lung cancer[J].ZHONGGUO YAOFANG,2022,33(22):2762-2765. DOI： 10.6039/j.issn.1001-0408.2022.22.15.

摘要

目的

观察白蛋白结合型紫杉醇治疗晚期非小细胞肺癌（NSCLC）的有效性及安全性。

方法

纳入我院2018年1月－2021年12月收治的晚期NSCLC患者的临床资料，根据其所用化疗方案分为白蛋白结合型紫杉醇组和紫杉醇组，每组100例。两组患者均接受含注射用紫杉醇（白蛋白结合型）或紫杉醇注射液的化疗方案治疗至少2个周期（每21 d为1个周期），比较两组患者的无进展生存期（PFS）和疗效，并记录毒副反应发生情况。

结果

白蛋白结合型紫杉醇组患者共完成化疗430个周期，平均4.3个周期；紫杉醇组患者共完成化疗476个周期，平均4.8个周期。白蛋白结合型紫杉醇组患者的中位PFS（4.0个月）、有效率（13.00%）与紫杉醇组（4.0个月、9.00%）比较，差异均无统计学意义（

＞0.05），其疾病控制率（99.00%）显著高于紫杉醇组（89.00%），其白细胞减少、中性粒细胞减少、血小板减少、贫血、感觉神经病变、乏力、恶心呕吐、关节肌痛的发生率均显著低于紫杉醇组（

＜0.05）。

结论

白蛋白结合型紫杉醇治疗晚期NSCLC的疗效较好，比普通紫杉醇能更好地控制疾病的进展，且安全性更高。

Abstract

OBJECTIVE

To observe the efficacy and safety of albumin-bound paclitaxel in the treatment of advanced non-small cell lung cancer （NSCLC）.

METHODS

Clinical data of patients with advanced NSCLC treated in our hospital from January 2018 to December 2021 were selected. According to their chemotherapy regimen，they were divided into albumin-bound paclitaxel group and paclitaxel group， with 100 patients in each group. Both groups received chemotherapy regimen containing Paclitaxel for injection （albumin-bound） or Paclitaxel injection for at least 2 cycles （every 21 days as a cycle）. The progression-free survival （PFS） and efficacy of the two groups were compared，and the occurrence of toxic and side effects were recorded.

RESULTS

The patients in albumin-bound paclitaxel group completed 430 cycles of chemotherapy， with an average of 4.3 cycles； patients in paclitaxel group completed 476 cycles of chemotherapy， with an average of 4.8 cycles. The median PFS （4.0 months） and the response rate （13.00%） of albumin-bound paclitaxel group were not significantly different from those of paclitaxel group （4.0 months，9.00%）（

＞0.05）. The disease control rate （99.00%） was significantly higher than that in paclitaxel group （89.00%）， and the incidences of leukopenia， neutropenia， thrombocytopenia，anemia， sensory neuropathy， fatigue，nausea and vomiting，joint myalgia in albumin-bound paclitaxel group were significantly lower than those in paclitaxel group （

＜0.05）.

CONCLUSIONS

Albumin-bound paclitaxel is effective in the treatment of advanced NSCLC， and it can better control the progression of the disease and is safer than ordinary paclitaxel.

关键词

白蛋白结合型紫杉醇紫杉醇晚期非小细胞肺癌有效性安全性

Keywords

paclitaxelnon-small cell lung cancerefficacysafety

references

搜狐网.国家癌症中心发布：2022全国癌症报告[EB/OL].[2022-04-25].https://www.sohu.com/a/583125477_121124574https://www.sohu.com/a/583125477_121124574.

NCCN. NCCN clinical practice guidelines in oncology：non-small cell lung cancer：version 1，2022[EB/OL].[2022-04-25]. https：//www.nccn.org/professionals/physician_gls/pdf/nscl.pdfhttps://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.

中国临床肿瘤学会指南工作委员会.2021 CSCO非小细胞肺癌诊疗指南[M].北京：人民卫生出版社，2020：27-137.

许菊青，夏文杰，蒋峰，等.富含半胱氨酸的酸性分泌蛋白在晚期肺鳞状细胞癌组织的表达及与白蛋白紫杉醇疗效的相关性[J].中华实验外科杂志，2016，33（1）：235-237.

石远凯，孙燕.临床肿瘤内科手册[M].6版.北京：人民卫生出版社，2018：322-324.

EISENHAUER E A，THERASSE P，BOGAERTS J，et al. New response evaluation criteria in solid tumours：revised RECIST guideline，version 1.1[J].Eur J Cancer，2009，45（2）：228-247.

U.S. Department of Health and Human Services，National Institutes of Health and National Cancer Institute. Common terminology criteria for adverse events（CTCAE），version 5.0[EB/OL].（2017-11-27）[2022-04-11]. https：//ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdfhttps://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf.

邵扣凤，刘燕文.不同剂型紫杉醇联合顺铂治疗晚期非小细胞肺癌的效果分析[J].临床肿瘤学杂志，2016，21（10）：893-897.

许红霞，梅静峰，王晓华，等. 白蛋白结合型紫杉醇联合卡铂治疗晚期初治非小细胞肺癌的临床观察[J]. 临床肿瘤学杂志，2013，18（12）：1117-1120.

王郁薇，蒙龙，刘箫. 基于美国FDA不良事件数据库的注射用紫杉醇（白蛋白结合型）不良反应信号挖掘[J]. 中国药房，2021，32（3）：328-333.

卢家彬，郭金成，张冬梅. 白蛋白结合型紫杉醇联合洛铂与顺铂治疗晚期非小细胞肺癌临床疗效比较[J]. 北方药学，2018，15（7）：112.

吴颖其，朱婷，童彤，等. 白蛋白结合型紫杉醇不良反应/事件相关因素分析[J]. 中国药物警戒，2022，19（10）：1123-1127.

承婷，孙清. 白蛋白结合型紫杉醇联合卡铂治疗晚期非小细胞肺癌的临床疗效观察[J/OL]. 肿瘤药学，2022：1-4（2022-03-18）[2022-04-25]. https：//kns.cnki.net/kcms/detail/43.1507.R.20220317.1026.006.htmlhttps://kns.cnki.net/kcms/detail/43.1507.R.20220317.1026.006.html.

周泽军，谢海燕，侯志波，等. 白蛋白结合型紫杉醇治疗晚期非小细胞肺癌的疗效及安全性[J]. 江苏医药，2021，47（11）：1169-1173.

梁百武，吴丹，柏茂树，等. 白蛋白结合型紫杉醇对比紫杉醇二线治疗晚期肺鳞癌回顾性分析[J]. 现代肿瘤医学，2021，29（11）：1899-1903.

杨宇，朱丹，孙科. 白蛋白结合型紫杉醇二线治疗晚期非小细胞肺癌的临床效果分析[J]. 中国现代药物应用，2021，15（22）：138-140.

苏家兴.白蛋白结合型紫杉醇联合顺铂治疗晚期非小细胞肺癌的临床效果[J].临床医学研究与实践，2022，7（2）：28-30.

朱绍光.白蛋白结合型紫杉醇二线治疗难治性复发小细胞肺癌疗效观察[J].海峡药学，2021，33（9）：130-132.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Efficacy and safety comparison of lacosamide and carbamazepine in the treatment of adult patients with newly diagnosed epilepsy

Efficacy and safety of aerosol inhalation of polycolistin B in patients with severe pneumonia combined with mechanical ventilation

Research progress of furmonertinib for EGFR-mutated non-small cell lung cancer

Clinical observation of icotinib versus gefitinib in the treatment of EGFR-mutated advanced non-small cell lung cancer

Efficacy and safety of olaparib in adjuvant therapy of BRCA1/2 mutated HER2-negative breast cancer： a meta-analysis

Related Author

GUO Xiaqing

LI Guofei

SUN Yuhua

ZHENG Donglin

YANG Yilei

ZHANG Hu

CAO Jia

YI Qiaoyan

Related Institution

First Ward， Dept. of Neurology， Huaihe Hospital of Henan University

Center for Big Data Research in Health and Medicine， the First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital

Dept. of Clinical Pharmacy， the First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital， Shandong Engineering and Technology Research Center for Pediatric Drug Development， Shandong Medicine and Health Key Laboratory of Clinical Pharmacy

Key Specialty of Clinical Pharmacy， the First Affiliated Hospital of Guangdong Pharmaceutical University

School of Pharmacy， Anhui University of Chinese Medicine

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰